Home / Stocks / Rpg Life Sciences Ltd
RPGLIFE

Rpg Life Sciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,606.1

Change

+103.6 (4.14%)

Open

₹2,518.2

Prev. Close

₹2,502.5

Day High

₹2,650.0

Day Low

₹2,460.1

Volume Analysis

Traded

16,199

Delivered

5,778

Delivery %

35.67%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,873.94 ₹2,761.97 ₹2,684.04 ₹2,572.07 ₹2,494.14 ₹2,382.17 ₹2,304.24
Fibonacci ₹2,761.97 ₹2,689.43 ₹2,644.61 ₹2,572.07 ₹2,499.53 ₹2,454.71 ₹2,382.17
Camarilla ₹2,658.32 ₹2,640.92 ₹2,623.51 ₹2,572.07 ₹2,588.69 ₹2,571.29 ₹2,553.88

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+12.69%

1 Week

+0.11%

1 Month

-6.84%

3 Months

-1.16%

6 Months

+13.61%

1 Year

+17.13%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹807.36

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

14.83%

Net margin 14.53% × asset turnover 0.63x × equity multiplier 1.62x

Company Overview

Sector

Healthcare

Market Cap

₹4,220 Cr

P/E (TTM)

36.8

ROE

19.3%

Book Value

₹416.0

Face Value

₹8.0

Source: Screener.in (Consolidated figures) — data as of 14 Nov 2026. Not investment advice.

TopFund Analysis

Rpg Life Sciences Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 62/100. The strongest factor is Financial Strength (100/100), while Cash Flow (15/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%).

TopFund Score — Fundamentals Quality

62/100 — Average

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

26

Cash Flow

15

Corporate Governance

90

Momentum

59

Institutional Ownership

47

Business Quality

86

Risk & Volatility

58

Liquidity

34

From Screener.in

  • +Company is almost debt free.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of Q2 FY27 earnings call made available online on October 30, 2026.

Board approved unaudited standalone and consolidated results for quarter and half-year ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 173 143 169 182 180 177 196 212
Expenses + 124 118 133 143 140 144 152 171
Operating Profit 49 25 35 39 40 33 44 40
OPM % 28.0% 18.0% 21.0% 21.0% 22.0% 19.0% 22.0% 19.0%
Other Income + 3 115 5 16 -5 14 4 4
Interest 0 0 0 0 0 0 1 1
Depreciation 5 5 5 5 5 6 6 7
Profit before tax 47 135 35 49 29 40 41 37
Tax % 26.0% 13.0% 26.0% 25.0% 24.0% 26.0% 26.0% 24.0%
Net Profit + 35 117 26 37 22 30 31 28
EPS in Rs 21 71 16 22 13 18 18 16
Raw PDF — — — — — — — —
YoY Sales growth — — — — 4 24 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2025 Mar 2026 TTM
Sales + 653 708 764
Expenses + 493 560 608
Operating Profit 161 148 157
OPM % 25.0% 21.0% 20.0%
Other Income + 95 29 17
Interest 2 2 2
Depreciation 21 21 24
Profit before tax 233 154 148
Tax % 21.0% 25.0% —
Net Profit + 183 115 111
EPS in Rs 111 70 66
Dividend Payout % 22.0% 34.0% —
Sales growth — 8 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2025 Mar 2026 Sep 2026
Reserves 517 592 674
Borrowings + 0 20 26
Other Liabilities + 127 168 403
Total Liabilities 658 793 1,116
Fixed Assets + 172 197 409
CWIP 16 23 20
Investments 127 85 165
Other Assets + 343 488 522
Total Assets 658 793 1,116
Equity Capital 13 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2025 Mar 2026
Cash from Operating Activity + 78 56
Cash from Investing Activity + -42 86
Cash from Financing Activity + -27 -21
Net Cash Flow 9 122
Free Cash Flow 151 -9
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 81 63

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 72.82% → 72.95%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 24.85% 24.12% 23.44% 20.4% 19.7% 19.46% 19.22% 19.23% 19.01% 18.72% 17.42% 16.24%
Promoters 72.82% 72.82% 72.82% 72.82% 72.95% 72.95% 72.95% 72.95% 72.95% 72.95% 72.95% 72.95%
FII 0.56% 0.9% 1.15% 1.35% 1.3% 1.46% 1.35% 1.11% 1.0% 0.87% 0.95% 0.87%
DII 1.77% 2.16% 2.61% 5.45% 6.06% 6.14% 6.49% 6.7% 7.04% 7.45% 8.68% 9.93%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Rpg Life Sciences Ltd (this stock) 4,220 36.8 6.13 19.3%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%

Which Mutual Funds Hold Rpg Life Sciences Ltd?

Frequently Asked Questions about Rpg Life Sciences Ltd

Community Sentiment

What are other investors saying about Rpg Life Sciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.